Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GSK 
GlaxoSmithKline PLC ADR (GSK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: GSK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $39.03
1 Year Target Price $39.03
| 1 | Strong Buy |
| 0 | Buy |
| 5 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -12.03% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 79.65B USD | Price to earnings Ratio 17.69 | 1Y Target Price 39.03 |
Price to earnings Ratio 17.69 | 1Y Target Price 39.03 | ||
Volume (30-day avg) 8 | Beta 0.27 | 52 Weeks Range 30.68 - 42.32 | Updated Date 08/29/2025 |
52 Weeks Range 30.68 - 42.32 | Updated Date 08/29/2025 | ||
Dividends yield (FY) 4.18% | Basic EPS (TTM) 2.23 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.82% | Operating Margin (TTM) 30.52% |
Management Effectiveness
Return on Assets (TTM) 6.79% | Return on Equity (TTM) 28.33% |
Valuation
Trailing PE 17.69 | Forward PE 8.79 | Enterprise Value 98892498645 | Price to Sales(TTM) 2.52 |
Enterprise Value 98892498645 | Price to Sales(TTM) 2.52 | ||
Enterprise Value to Revenue 2.32 | Enterprise Value to EBITDA 8.5 | Shares Outstanding 2014589952 | Shares Floating 3910575630 |
Shares Outstanding 2014589952 | Shares Floating 3910575630 | ||
Percent Insiders 0.06 | Percent Institutions 19.07 |
Upturn AI SWOT
GlaxoSmithKline PLC ADR
Company Overview
History and Background
GlaxoSmithKline (GSK) was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham. Its roots trace back to the 18th century. It has evolved through numerous mergers and acquisitions to become a global pharmaceutical leader.
Core Business Areas
- Pharmaceuticals: Develops, manufactures, and markets a range of prescription medicines to treat diseases, including respiratory, HIV, oncology, and immunology. Focuses on innovative medicines and vaccines.
- Vaccines: Offers a broad portfolio of vaccines protecting against diseases such as influenza, meningitis, hepatitis, and shingles. Aims to prevent disease through immunization.
- Consumer Healthcare: Develops and markets over-the-counter medicines, oral health products, and nutritional supplements. In 2022, GSK spun off its consumer healthcare division into Haleon (HLN), of which GSK retained a minority stake.
Leadership and Structure
The CEO of GlaxoSmithKline is Emma Walmsley. The company operates under a board of directors and is organized into various research, development, and commercial divisions.
Top Products and Market Share
Key Offerings
- Arexvy: A vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in older adults. Competitors are Pfizer's Abrysvo and Moderna's mRNA-1345. In 2023, Arexvy generated $1.24 billion in revenue.
- Duvroq: A medication for the treatment of anemia associated with chronic kidney disease (CKD). Main competitors are Akebia Therapeutics and FibroGen. In 2023, GSK generated $36 million in revenue from Duvroq.
- Shingrix: A vaccine for the prevention of shingles (herpes zoster) in adults aged 50 years and older. In 2023, Shingrix generated about u00a33.4 billion in sales. Competitors include Merck's Zostavax (although it's no longer widely used) and potentially future mRNA-based vaccines from companies like Moderna and BioNTech.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and a competitive landscape driven by innovation. It is experiencing growth in areas such as biologics, personalized medicine, and vaccines.
Positioning
GSK is a major player in the pharmaceutical and vaccine industries. It aims for leadership in these sectors through research and development, strategic partnerships, and acquisitions.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated to be over $1 trillion. GSK aims to capture a significant share of this market through its diversified portfolio and innovation pipeline.
Upturn SWOT Analysis
Strengths
- Strong research and development capabilities
- Diversified product portfolio
- Global presence and distribution network
- Established brand reputation
- Strong vaccine portfolio
Weaknesses
- Reliance on key products
- Exposure to patent expirations
- Potential for regulatory setbacks
- Dependence on partnerships
- Generic competition
Opportunities
- Growth in emerging markets
- Development of new therapies and vaccines
- Strategic acquisitions and partnerships
- Expanding focus on specialty medicines
- Advancements in personalized medicine
Threats
- Increased competition from generic drug manufacturers
- Pricing pressures from governments and payers
- Product liability lawsuits
- Changes in healthcare regulations
- Economic downturns
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- MRK
- NVS
- SNY
Competitive Landscape
GSK competes with other major pharmaceutical companies in the development and marketing of prescription drugs and vaccines. Competition is driven by innovation, pricing, and market access. GSK tries to differentiate itself with its novel pipeline and vaccine business. The market share data is for the global pharmaceutical market and not just in the US.
Major Acquisitions
Affinivax
- Year: 2022
- Acquisition Price (USD millions): 2100
- Strategic Rationale: Acquired Affinivax to bolster its vaccine pipeline with innovative technology and broaden its vaccine portfolio.
Sierra Oncology
- Year: 2022
- Acquisition Price (USD millions): 1900
- Strategic Rationale: Acquired Sierra Oncology to strengthen its oncology pipeline, specifically with momelotinib, a potential treatment for myelofibrosis.
Growth Trajectory and Initiatives
Historical Growth: GSK's historical growth is influenced by factors such as product launches, acquisitions, and market conditions. This data would come from historical financial data.
Future Projections: Analyst estimates for GSK's future growth vary depending on factors such as the success of its pipeline products and market trends. Analyst reports provide these projections.
Recent Initiatives: Recent strategic initiatives include focusing on innovative medicines and vaccines, restructuring the consumer healthcare business (Haleon spinoff), and investing in research and development.
Summary
GSK is a large pharmaceutical company with a strong presence in vaccines and prescription drugs. Recent strategic moves include the spin-off of its consumer healthcare business, Haleon. While GSK has a robust pipeline, it faces competition from other major pharmaceutical companies and potential regulatory challenges. GSK looks to continue to grow through innovation and future acquisitions and its vaccine business is highly valuable.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Financial News Outlets
- Company Website
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on your own research and consultation with a qualified financial advisor. Market share data is approximate and based on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GlaxoSmithKline PLC ADR
Exchange NYSE | Headquaters - | ||
IPO Launch date 1986-07-09 | CEO & Director Ms. Emma Natasha Walmsley | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 68629 | Website https://www.gsk.com |
Full time employees 68629 | Website https://www.gsk.com | ||
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.